Fulltext

Valaciclovir for Chronic Hepatitis BVirus Infection after Lung Transplantation

Laube, I. ; Boehler, A. ; Renner, E. ; Speich, R.

In: Infection, 2004, vol. 32, no. 1, p. 51-53

Ajouter à la liste personnelle
    Titre
    • Valaciclovir for Chronic Hepatitis BVirus Infection after Lung Transplantation
    Auteur
    • Laube, I.. Dept. of Internal Medicine, University Hospital Zurich, Raemistr. 100, CH- 8091, Zurich, Switzerland
    • Boehler, A.. Dept. of Internal Medicine, University Hospital Zurich, Raemistr. 100, CH- 8091, Zurich, Switzerland
    • Renner, E.. Dept. of Internal Medicine, University Hospital Zurich, Raemistr. 100, CH- 8091, Zurich, Switzerland
    • Speich, R.. Dept. of Internal Medicine, University Hospital Zurich, Raemistr. 100, CH- 8091, Zurich, Switzerland
    Type de document
    • Postprint
    Classification
    • Santé
    Identifiant OAI-PMH
    • oai:doc.rero.ch:314661
    Summary
    Abstract. : We report on a chronic asymptomatic hepatitis B surface antigen (HBsAg) carrier who developed an increase in aminotransferase and HBsAg levels 1 year after lung transplantation. During treatment for cutaneous herpes simplex virus (HSV) infection with oral valaciclovir there was a marked decrease in replicating hepatitis B virus (HBV)-DNA and aminotransferase levels, which was sustained for 9 months by continuing low-dose valaciclovir. A second rise in aminotransferase levels again responded to a valaciclovir dose increase and the HBV-DNA levels declined further. Although we cannot exclude a spontaneous variation of the serologic parameters, our observation suggests that valaciclovir may represent a valuable therapeutic option in the treatment of chronic hepatitis B after lung transplantation